Varian Medical (NYSE:VAR) said today it acquired privately-held HumediQ, which develops the Identify automated patient identification, positioning and management system for radiation therapy, for an undisclosed amount.
Palo Alto, Calif.-based Varian said the acquisition was made to expand its motion-management portfolio as part of its “long-term growth and value creation strategy.”
“Varian is focused on enabling sophisticated high-quality cancer care safely and effectively, around the globe. Varian and HumediQ Global share a common mission in the worldwide fight against cancer and we are pleased to welcome the HumediQ Global employees to the expanding Varian family in the region and add the comprehensive Identify solution to our portfolio,” Varian oncology systems biz prez Kolleen Kennedy said in a prepared statement.
HumediQ’s Identify is designed as an automated workflow solution for surface-guided radiation therapy and features a palm reader for patient identification, radio frequency identification reader, automatic synchronization with oncology IT systems and SGRT cameras for patient positioning and motion monitoring.
“The Identify solution combines improved patient safety, an enhanced clinical workflow and surface guided imaging for high-quality radiation therapy treatments. We are excited to join Varian and bring this solution to as many patients as possible worldwide. We share a passion for innovation, quality, and patient centered care and look forward to continue that mission together,” HumediQ global CEO Christian Hieronimi said in a press release.
Last month, Varian Medical saw shares rise in after-hours trading after the medical device maker beat expectations on Wall Street with its third quarter fiscal year 2018 earnings results.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.